Moreover, use of bupropion, which suppresses TNFα production, significantly lowered the risk of developing POAG in humans in a large retrospective study [41], while anti-TNFα medication (etanercept) was found to be neuroprotective in a rodent model of glaucoma [42]. This evidence concerns the gene TNF and glaucoma.